Emma Walmsley

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine, which was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated $1.6 billion in sales in its first year after launching in the third quarter of 2023. Sales of Shingrix, its shingles vaccine, are also booming. GSK recorded $37.5 billion in revenue in 2023, up 3.4% from the previous year. Outside of GSK, Walmsley is also an independent director at Microsoft.